Capecitabine

Researchers are evaluating whether combining electroacupuncture with self-administered acupressure and doctor-prescribed treatments can help prevent Hand-Foot Syndrome (HFS) in patients with malignant tumors undergoing oral capecitabine therapy. The study is a randomized, triple-blinded controlled trial designed to explore the preventive effects of this combined approach on HFS and to improve quality of life during cancer treatment. Participants are randomly assigned to receive either true electroacupuncture plus true self-administered acupressure along with doctor-prescribed medications, or sham electroacupuncture plus sham self-administered acupressure with the same medications. True electroacupuncture involves two treatments in the first week of each cycle with electrical stimulation, followed by self-administered acupressure in weeks 2 and 3. The doctor-prescribed treatment includes oral celecoxib, topical diclofenac, and skin protectants. The sham group receives minimally invasive needle insertion without electrical stimulation and non-acupressure point massage without pressure causing the "deqi" sensation, but with the same medication regimen. During the study, participants are monitored for HFS incidence, severity, onset, duration, and pain or sensory changes from the start of capecitabine treatment until 12 weeks after treatment ends. The HFS-14 questionnaire is used regularly to assess patient-reported symptoms and adverse events. Researchers track capecitabine dosage, HFS grades, and quality of life to understand treatment impact. The study duration and follow-up allow thorough evaluation of the combined preventive approach.

Researchers are evaluating the combination of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) with Cadonilimab as a first-line treatment for patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have not yet received systemic therapy. This Phase II, single-center study aims to assess the safety and effectiveness of this regimen in treating locally advanced or metastatic PDAC. The treatment involves cycles every two weeks including Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, and Capecitabine, with specific dosing schedules. After three cycles, patients are re-evaluated, and those treated for more than nine cycles may enter maintenance therapy with Capecitabine and Cadonilimab. This approach studies continuous dosing and maintenance to manage advanced PDAC. Participants will undergo regular assessments including tumor response evaluations according to RECIST 1.1 criteria, safety monitoring for adverse events, and other efficacy measures like progression-free and overall survival over two years. Organ function, performance status, and other health indicators will be closely monitored to track treatment impact and patient safety throughout the study period.

Researchers are evaluating a combination treatment for patients with oligometastatic nasopharyngeal carcinoma, a type of cancer that has spread but only to a limited number of sites. This phase II clinical trial is designed to assess how effective and safe multi-target radiotherapy combined with a PD-1 monoclonal antibody and capecitabine maintenance therapy is for this condition. The study also aims to explore genetic markers and develop models to predict which patients may benefit from this treatment approach. Participants will receive a combination of radiotherapy, chemotherapy, and immunotherapy. Radiotherapy involves intensity-modulated radiation therapy (IMRT) targeting primary tumor sites and cervical lymph nodes, along with stereotactic body radiation therapy (SBRT) directed at oligometastatic sites. The PD-1 inhibitor is administered intravenously every three weeks throughout the trial. Capecitabine is taken orally twice daily at 650 mg following radiotherapy and continued for one year as maintenance therapy. During the study, participants will be closely monitored through various assessments to evaluate treatment response, progression-free survival at two years, overall survival, and duration of response. Researchers will also gather safety data and explore potential genetic biomarkers related to treatment efficacy. The total participation period includes treatment and follow-up visits to track outcomes and safety until the study concludes.

This research evaluates the combination of UTD1 and capecitabine in patients with metastatic HER2-negative breast cancer who also have brain metastases. It is a single-arm, multicenter, open-label clinical study aiming to assess how effective and safe this combined treatment is for this specific patient group. Participants receive UTD1 at a dose of 30 mg/m2 daily for 5 days in each 21-day treatment cycle, along with capecitabine taken orally at 2000 mg/m2 daily for 14 days per 21-day cycle. The treatment continues under close observation as part of this phase 1 and phase 2 study. During the study, patients undergo regular brain MRI scans and other laboratory tests to monitor treatment response and safety. The main measure is the central nervous system objective response rate assessed up to one year. Additional outcomes include clinical benefit rate, progression-free survival, and response rates, with careful tracking of side effects and overall health throughout the participation period.

Researchers are evaluating the combination of XELOX (oxaliplatin and capecitabine), bevacizumab, and tislelizumab for treating patients with MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. This phase II study aims to assess the safety and effectiveness of this regimen, which is designed to turn RAS-mutated colorectal cancer into a "hot tumor" to improve response through combined chemotherapy, anti-vascular therapy, and immunotherapy. Participants receive treatment in cycles every three weeks. Each cycle includes intravenous tislelizumab (200 mg), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m2) on day 1, plus oral capecitabine (1000 mg/m2 twice daily) for 14 days. After eight cycles, patients enter maintenance therapy with capecitabine, bevacizumab, and tislelizumab. Patients are re-evaluated every two cycles to monitor progress. During the study, participants undergo assessments of tumor response, safety, and disease progression over two years, including measuring the objective response rate. Additional outcomes include duration of response, disease control rate, progression-free survival, overall survival, and treatment-related side effects. The study is designed to last up to five years for some outcomes, with ongoing monitoring for safety and effectiveness.